ID NS8_SARS2 Reviewed; 121 AA.
AC P0DTC8;
DT 22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT 22-APR-2020, sequence version 1.
DT 27-MAR-2024, entry version 20.
DE RecName: Full=ORF8 protein;
DE Short=ORF8;
DE AltName: Full=Non-structural protein 8;
DE Short=ns8;
DE Flags: Precursor;
GN ORFNames=8;
OS Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC Betacoronavirus; Sarbecovirus;
OC Severe acute respiratory syndrome coronavirus.
OX NCBI_TaxID=2697049;
OH NCBI_TaxID=9606; Homo sapiens (Human).
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT "A new coronavirus associated with human respiratory disease in China.";
RL Nature 579:265-269(2020).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC STRAIN=isolate 2019-nCoV_HKU-SZ-002a_2020;
RX PubMed=31986261; DOI=10.1016/s0140-6736(20)30154-9;
RA Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J.,
RA Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M.,
RA Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y.;
RT "A familial cluster of pneumonia associated with the 2019 novel coronavirus
RT indicating person-to-person transmission: a study of a family cluster.";
RL Lancet 395:514-523(2020).
RN [3]
RP MISCELLANEOUS.
RX PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT "Characterization of accessory genes in coronavirus genomes.";
RL Virol. J. 17:131-131(2020).
RN [4]
RP MISCELLANEOUS.
RX PubMed=32807944; DOI=10.1038/s41590-020-0773-7;
RA Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P.,
RA Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M.,
RA Valkenburg S.A.;
RT "ORF8 and ORF3b antibodies are accurate serological markers of early and
RT late SARS-CoV-2 infection.";
RL Nat. Immunol. 21:1293-1301(2020).
RN [5]
RP INTERACTION WITH HUMAN IL17RA, AND SUBCELLULAR LOCATION.
RX PubMed=33060197; DOI=10.1126/science.abe9403;
RG QCRG Structural Biology Consortium;
RG Zoonomia Consortium;
RA Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT "Comparative host-coronavirus protein interaction networks reveal pan-viral
RT disease mechanisms.";
RL Science 0:0-0(2020).
RN [6]
RP INTERACTION WITH HUMAN IL17RA, AND FUNCTION.
RX PubMed=33723527; DOI=10.1016/j.isci.2021.102293;
RA Lin X., Fu B., Yin S., Li Z., Liu H., Zhang H., Xing N., Wang Y., Xue W.,
RA Xiong Y., Zhang S., Zhao Q., Xu S., Zhang J., Wang P., Nian W., Wang X.,
RA Wu H.;
RT "Title: ORF8 contributes to cytokine storm during SARS-CoV-2 infection by
RT activating IL-17 pathway.";
RL IScience 1:102293-102293(2021).
RN [7]
RP VARIANT SER-84.
RX PubMed=32615316; DOI=10.1016/j.meegid.2020.104445;
RA Laha S., Chakraborty J., Das S., Manna S.K., Biswas S., Chatterjee R.;
RT "Characterizations of SARS-CoV-2 mutational profile, spike protein
RT stability and viral transmission.";
RL Infect. Genet. Evol. 85:104445-104445(2020).
RN [8]
RP VARIANT 28-HIS--ILE-121 DEL.
RC STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT "Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT 2 in the United Kingdom, October to November 2020.";
RL Eurosurveillance 26:0-0(2021).
RN [9]
RP FUNCTION, AND SUBCELLULAR LOCATION.
RX PubMed=34177923; DOI=10.3389/fimmu.2021.679482;
RA Geng H., Subramanian S., Wu L., Bu H.F., Wang X., Du C., De Plaen I.G.,
RA Tan X.D.;
RT "SARS-CoV-2 ORF8 Forms Intracellular Aggregates and Inhibits IFNgamma-
RT Induced Antiviral Gene Expression in Human Lung Epithelial Cells.";
RL Front. Immunol. 12:679482-679482(2021).
RN [10]
RP FUNCTION, AND INTERACTION WITH HOST MHC-I.
RX PubMed=34021074; DOI=10.1073/pnas.2024202118;
RA Zhang Y., Chen Y., Li Y., Huang F., Luo B., Yuan Y., Xia B., Ma X.,
RA Yang T., Yu F., Liu J., Liu B., Song Z., Chen J., Yan S., Wu L., Pan T.,
RA Zhang X., Li R., Huang W., He X., Xiao F., Zhang J., Zhang H.;
RT "The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-
RT regulating MHC-Iota.";
RL Proc. Natl. Acad. Sci. U.S.A. 118:1-12(2021).
RN [11]
RP FUNCTION, SUBCELLULAR LOCATION, HOMODIMERIZATION, MUTAGENESIS OF CYS-20 AND
RP ASN-78, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-78.
RX PubMed=35157849; DOI=10.1016/j.jbc.2022.101724;
RA Matsuoka K., Imahashi N., Ohno M., Ode H., Nakata Y., Kubota M.,
RA Sugimoto A., Imahashi M., Yokomaku Y., Iwatani Y.;
RT "SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a
RT glycoprotein homodimer.";
RL J. Biol. Chem. 1:101724-101724(2022).
RN [12]
RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HUMAN IL17RA, AND
RP MUTAGENESIS OF SER-24; TYR-42; VAL-62; ILE-71; ILE-76; LEU-84 AND GLU-106.
RX PubMed=35343786; DOI=10.1128/mbio.00402-22;
RA Wu X., Xia T., Shin W.J., Yu K.M., Jung W., Herrmann A., Foo S.S., Chen W.,
RA Zhang P., Lee J.S., Poo H., Comhair S.A.A., Jehi L., Choi Y.K., Ensser A.,
RA Jung J.U.;
RT "Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8.";
RL MBio 1:e0040222-e0040222(2022).
RN [13]
RP FUNCTION, MUTAGENESIS OF 1-MET--PHE-16 AND ASN-78, AND SUBCELLULAR
RP LOCATION.
RX PubMed=36689483; DOI=10.1371/journal.ppat.1011128;
RA Lin X., Fu B., Xiong Y., Xing N., Xue W., Guo D., Zaky M., Pavani K.,
RA Kunec D., Trimpert J., Wu H.;
RT "Unconventional secretion of unglycosylated ORF8 is critical for the
RT cytokine storm during SARS-CoV-2 infection.";
RL PLoS Pathog. 19:e1011128-e1011128(2023).
RN [14]
RP X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 18-121, AND DISULFIDE BOND.
RA Nelson C.A., Hall P.D., Fremont D.H.;
RT "Crystal Structure of the SARS-CoV-2 ORF8 Protein.";
RL Submitted (AUG-2020) to the PDB data bank.
RN [15]
RP X-RAY CRYSTALLOGRAPHY (2.04 ANGSTROMS) OF 18-121, DISULFIDE BOND, AND
RP HOMODIMERIZATION.
RX PubMed=33361333; DOI=10.1073/pnas.2021785118;
RA Flower T.G., Buffalo C.Z., Hooy R.M., Allaire M., Ren X., Hurley J.H.;
RT "Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein.";
RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
CC -!- FUNCTION: Plays a role in modulating the host immune response
CC (PubMed:31986261, PubMed:35343786, PubMed:36689483). May act as a
CC secreted virokine by mimicking interleukin-17A (IL17A), and thereby
CC binding to the IL17RA receptor, leading to activation of the IL17
CC pathway and increased secretion of pro-inflammatory factors
CC (PubMed:35343786, PubMed:36689483). Contributes to the cytokine storm
CC during SARS-CoV-2 infection when secreted by unconventional pathway
CC (PubMed:33723527, PubMed:36689483). May act by down-regulating major
CC histocompability complex class I (MHC-I) at cell surface
CC (PubMed:34021074, PubMed:35157849). May inhibit expression of some
CC members of the IFN-stimulated gene (ISG) family including hosts
CC IGF2BP1/ZBP1, MX1 and MX2, and DHX58 (PubMed:34177923).
CC {ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:34021074,
CC ECO:0000269|PubMed:34177923, ECO:0000269|PubMed:35157849,
CC ECO:0000269|PubMed:35343786, ECO:0000269|PubMed:36689483,
CC ECO:0000303|PubMed:31986261}.
CC -!- SUBUNIT: Homodimer (PubMed:33361333, PubMed:35157849). Interacts with
CC host IL17RA (PubMed:33060197, PubMed:35343786). Interacts with host
CC IL17RC (PubMed:35343786). Interacts with host MHC-I (PubMed:34021074).
CC {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33361333,
CC ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:35157849,
CC ECO:0000269|PubMed:35343786}.
CC -!- INTERACTION:
CC P0DTC8; P0DTC8: 8; NbExp=3; IntAct=EBI-25475900, EBI-25475900;
CC P0DTC8; Q9UHI8: ADAMTS1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-2511802;
CC P0DTC8; Q8N766: EMC1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-1044442;
CC P0DTC8; P01892: HLA-A; Xeno; NbExp=5; IntAct=EBI-25475900, EBI-2839473;
CC P0DTC8; Q96F46: IL17RA; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-5591258;
CC PRO_0000449655; PRO_0000449655 [P0DTC8]: 8; NbExp=2; IntAct=EBI-28965865, EBI-28965865;
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:35157849,
CC ECO:0000269|PubMed:35343786}. Note=Is secreted during a normal viral
CC infection by unconventional pathway (PubMed:35157849, PubMed:36689483).
CC Its mRNA is expressed in cytoplasm and not spliced during a viral
CC infection, but is spliced when expressed from cDNA in nucleus
CC (PubMed:35157849). Splicing changes localization to host endosome
CC and/or cytoplasm (PubMed:33060197, PubMed:34177923). May also localize
CC in nucleus when fused with GFP (PubMed:34177923).
CC {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34177923,
CC ECO:0000269|PubMed:35157849}.
CC -!- PTM: Glycosylated by the host when secreted via the conventional
CC pathway. The glycosylated form cannot bind IL17A and would not
CC participate in the cytokine storm. {ECO:0000269|PubMed:36689483}.
CC -!- POLYMORPHISM: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC 202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC {ECO:0000305|PubMed:33413740}.
CC -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC isolated in South Africa (November 2021). {ECO:0000305}.
CC -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC isolated in Nigeria (November 2022). {ECO:0000305}.
CC -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC isolated in United States (November 2022). It is the result of
CC recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC express ORF8. {ECO:0000305}.
CC -!- MISCELLANEOUS: Similar to some Bat coronavirus ns8 genes, but is
CC entirely different from SARS ns8a or Ns8b (Probable). Elicits strong
CC specific antibody response (PubMed:32807944).
CC {ECO:0000269|PubMed:32807944, ECO:0000305|PubMed:32854725}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; MN908947; QHD43422.1; -; Genomic_RNA.
DR EMBL; MN938384; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR PDB; 7F5F; X-ray; 1.62 A; A=18-121.
DR PDB; 7JTL; X-ray; 2.04 A; A/B=18-121.
DR PDB; 7JX6; X-ray; 1.61 A; A/B=18-121.
DR PDB; 7MX9; X-ray; 2.60 A; A=15-121.
DR PDB; 7XMN; X-ray; 2.30 A; B=16-121.
DR PDBsum; 7F5F; -.
DR PDBsum; 7JTL; -.
DR PDBsum; 7JX6; -.
DR PDBsum; 7MX9; -.
DR PDBsum; 7XMN; -.
DR SMR; P0DTC8; -.
DR BioGRID; 4383873; 1295.
DR ComplexPortal; CPX-6147; SARS-CoV-2 ORF8 complex.
DR IntAct; P0DTC8; 151.
DR MINT; P0DTC8; -.
DR GlyGen; P0DTC8; 1 site.
DR AGR; RefSeq:YP_009724396; -.
DR Reactome; R-HSA-448424; Interleukin-17 signaling.
DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR PRO; PR:P0DTC8; -.
DR Proteomes; UP000464024; Genome.
DR Proteomes; UP000464747; Genome.
DR GO; GO:0005783; C:endoplasmic reticulum; IDA:ComplexPortal.
DR GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR GO; GO:0005615; C:extracellular space; IDA:UniProt.
DR GO; GO:0005764; C:lysosome; IDA:ComplexPortal.
DR GO; GO:0005125; F:cytokine activity; IDA:UniProt.
DR GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR GO; GO:0002891; P:positive regulation of immunoglobulin mediated immune response; IDA:ComplexPortal.
DR GO; GO:0046776; P:suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I; IDA:ComplexPortal.
DR GO; GO:0019049; P:virus-mediated perturbation of host defense response; IDA:UniProt.
DR CDD; cd21641; ORF8-Ig_SARS-CoV-2-like; 1.
DR InterPro; IPR022722; ORF8_betacoronavirus.
DR InterPro; IPR044391; ORF8_SARS-CoV-2-like.
DR InterPro; IPR046444; SARS_ORF8_IG.
DR Pfam; PF12093; bCoV_NS8; 1.
DR PROSITE; PS51964; SARS_ORF8_IG; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Disulfide bond;
KW Evasion of host immunity by viral interleukin-like protein; Glycoprotein;
KW Host-virus interaction; Reference proteome; Secreted; Signal;
KW Viral immunoevasion.
FT SIGNAL 1..15
FT /evidence="ECO:0000255"
FT CHAIN 16..121
FT /note="ORF8 protein"
FT /id="PRO_0000449655"
FT DOMAIN 19..121
FT /note="SARS ORF8 Ig-like"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01309"
FT CARBOHYD 78
FT /note="N-linked (GlcNAc...) (complex) asparagine; by host"
FT /evidence="ECO:0000269|PubMed:35157849,
FT ECO:0000269|PubMed:36689483"
FT DISULFID 20
FT /note="Interchain"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01309,
FT ECO:0000269|PubMed:33361333, ECO:0000269|PubMed:35157849"
FT DISULFID 25..90
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01309,
FT ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14"
FT DISULFID 37..102
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01309,
FT ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14"
FT DISULFID 61..83
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01309,
FT ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14"
FT VARIANT 2
FT /note="K -> Q (in strain: Theta/P.3)"
FT /evidence="ECO:0000305"
FT VARIANT 8..121
FT /note="Missing (in strain: Omicron/XBB.1.5, Omicron/
FT EG.5.1)"
FT /evidence="ECO:0000305"
FT VARIANT 11
FT /note="T -> I (in strain: Iota/B.1.526)"
FT /evidence="ECO:0000305"
FT VARIANT 11
FT /note="T -> K (in strain: Mu/B.1.621)"
FT /evidence="ECO:0000305"
FT VARIANT 28..121
FT /note="Missing (in strain: B.1.1.7)"
FT /evidence="ECO:0000305|PubMed:33413740"
FT VARIANT 38
FT /note="P -> S (in strain: Mu/B.1.621)"
FT /evidence="ECO:0000305"
FT VARIANT 84
FT /note="L -> S"
FT /evidence="ECO:0000305, ECO:0000305|PubMed:32615316"
FT VARIANT 92
FT /note="E -> K (in strain: Gamma/P.1)"
FT /evidence="ECO:0000305"
FT VARIANT 119
FT /note="D -> I (in strain: Delta/B.1.617.2)"
FT /evidence="ECO:0000305"
FT VARIANT 120..121
FT /note="Missing (in strain: Delta/B.1.617.2)"
FT /evidence="ECO:0000305"
FT MUTAGEN 1..16
FT /note="Missing: Partial loss of secretion."
FT /evidence="ECO:0000269|PubMed:36689483"
FT MUTAGEN 20
FT /note="C->A: Complete loss of dimerization."
FT /evidence="ECO:0000269|PubMed:35157849"
FT MUTAGEN 24
FT /note="S->L: Partial loss of hIL-17RC binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT MUTAGEN 42
FT /note="Y->H: Complete loss of hIL-17RA binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT MUTAGEN 62
FT /note="V->L: Partial loss of hIL-17RC binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT MUTAGEN 71
FT /note="I->D: Complete loss of hIL-17RC binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT MUTAGEN 76
FT /note="I->D: Complete loss of hIL-17RC binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT MUTAGEN 78
FT /note="N->D: Complete loss of N-glycosylation and of
FT secretion."
FT /evidence="ECO:0000269|PubMed:35157849"
FT MUTAGEN 78
FT /note="N->Q: Complete loss of glycosylation when secreted
FT by conventional route. Increases cytokine storm effects."
FT /evidence="ECO:0000269|PubMed:36689483"
FT MUTAGEN 84
FT /note="L->S: Complete loss of IL17RA binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT MUTAGEN 106
FT /note="E->P: Complete loss of hIL-17RA binding."
FT /evidence="ECO:0000269|PubMed:35343786"
FT STRAND 19..25
FT /evidence="ECO:0007829|PDB:7JX6"
FT STRAND 29..32
FT /evidence="ECO:0007829|PDB:7JX6"
FT STRAND 41..49
FT /evidence="ECO:0007829|PDB:7JX6"
FT STRAND 57..70
FT /evidence="ECO:0007829|PDB:7JX6"
FT TURN 74..78
FT /evidence="ECO:0007829|PDB:7F5F"
FT STRAND 80..82
FT /evidence="ECO:0007829|PDB:7JX6"
FT TURN 83..86
FT /evidence="ECO:0007829|PDB:7JX6"
FT STRAND 87..91
FT /evidence="ECO:0007829|PDB:7JX6"
FT STRAND 96..105
FT /evidence="ECO:0007829|PDB:7JX6"
FT STRAND 112..120
FT /evidence="ECO:0007829|PDB:7JX6"
SQ SEQUENCE 121 AA; 13831 MW; 912AD9E147A64907 CRC64;
MKFLVFLGII TTVAAFHQEC SLQSCTQHQP YVVDDPCPIH FYSKWYIRVG ARKSAPLIEL
CVDEAGSKSP IQYIDIGNYT VSCLPFTINC QEPKLGSLVV RCSFYEDFLE YHDVRVVLDF
I
//